A TWO-ARM, SINGLE CENTER PHASE 1B TRIAL OF BAVITUXIMAB PLUS IPILIMUMAB IN ADVANCED MELANOMA PATIENTS

Trial Profile

A TWO-ARM, SINGLE CENTER PHASE 1B TRIAL OF BAVITUXIMAB PLUS IPILIMUMAB IN ADVANCED MELANOMA PATIENTS

Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 Jan 2017

At a glance

  • Drugs Bavituximab (Primary) ; Ipilimumab
  • Indications Malignant melanoma
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 28 Dec 2016 Status changed from active, no longer recruiting to discontinued.
    • 10 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 23 Apr 2014 Status changed from not yet recruiting to recruiting, as reported by a Peregrine Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top